Recent News

• 01.28.2026 - Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
• 01.27.2026 - Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
• 01.14.2026 - AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
• 01.11.2026 - Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
• 01.11.2026 - Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
• 01.11.2026 - Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
• 01.05.2026 - Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
• 12.24.2025 - S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
• 12.19.2025 - Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
• 12.12.2025 - Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

Recent Filings

• 01.28.2026 - EX-99.1 EX-99.1
• 01.28.2026 - 8-K Current report
• 01.12.2026 - EX-99.1 EX-99.1
• 01.12.2026 - 8-K Current report
• 12.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.12.2025 - 144 Report of proposed sale of securities
• 12.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.11.2025 - 8-K Current report